Manufacturing of CAR-T therapies is a complex process with high costs and variability that require limitations to be overcome – production of LVV and LVV transduction of target cells.
Boosting LVV yields coupled with enhanced transduction efficiency can provide significant benefits for efficiency of CAR-T production, reducing manufacturing COGs, manufacturing timelines, overall product quality and patient access
Data package generated would provide test-case and GMP ready baseline process for more cost-effective production of cell therapies. This project will de-risk adoption of VSE™ by AstraZeneca and other developers of cell therapies.
VSETM formulations would be available for access by NIIMBL community and global biomanufacturing sector through supply agreement as appropriate
Reduction in the costs of therapies, improvements in quality of life for patients affected by chronic diseases and economic growth will all result from this project, and all align well with general government initiatives in Canada and the US.
Distribution of critical shared material, establishment of production and analytical SOPs.
Formulation for enhanced production of LVV
Formulation for enhanced LVV transduction of T-cells
Partner verification of Segment 2 formulation in in-house platform
Partner verification of VSE™ formulations in end-to-end CAR-T production in clinical candidate with CQA analysis; benchmarked against standard process
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Virica Biotech Inc.
AstraZeneca
Sartorius Stedim
